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1  | INTRODUCTION
Hepatitis E virus (HEV) is a RNA virus considered endemic in many 
areas of Asia and Africa, with sporadic outbreaks related to geno-
type 1 infection reported in people that consume contaminated food 
or water.1 When isolated cases occur in immunocompetent hosts, 
HEV infection is usually self- limited or subclinical unless the host 
is a pregnant woman, in which the reported mortality is as high as 
50%.2 The mechanisms related to fulminant hepatic failure dur-
ing HEV infection in pregnancy remain unclear although hormonal 
alterations have shown to play a role.3,4 In recent years, immuno-
compromised individuals have been shown to develop chronic infec-
tion or reactivation of HEV, mainly due to infection with genotype 
3.5,6 This effect is more evident in patients receiving a solid organ 
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Abstract
Background and Aims: Infection with Hepatitis E virus (HEV) can cause chronic liver 
disease in immunocompromised hosts. In transplant recipients, the use of certain immu-
nosuppressants and food habits has been proposed as risk factors for HEV. In individuals 
infected with the human immunodeficiency virus (HIV), risk factors for HEV infection are 
less clear. We aimed to study the association between a mutation in the progesterone 
receptor (PR) named PROGINS and HEV- infected in HIV- positive individuals.
Methods: We evaluated the presence of the SNP PROGINS via KASP in serum sam-
ples of 64 HIV- positive individuals and 187 healthy controls. We performed ELISA 
tests to address the serum levels of IL- 10 and IL- 12, as well as T- cell stimulation assays 
in peripheral blood to address immune response in individuals with PROGINS.
Results: We found a significant association between the presence of PROGINS muta-
tion and HEV seroprevalence in individuals infected with HIV (30% in HIV+/HEV+ 
versus 2% in HIV+/HEV, respectively, P = .009). Moreover, we found that HIV+/HEV+ 
individuals expressing the PROGINS mutation had lower serum levels of IL- 10 and 
higher levels of IL- 12. The presence of the mutation led to a reduced response upon 
stimulation of CD4+ and CD8+ T cells compared to those without the mutation, sug-
gesting an immune modulation associated with PROGINS.
Conclusions: Our study identified a mutation in the PR that provides significant in-
sights into mechanisms of HEV infection in immunosuppressed individuals.
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transplant, but can occur in other forms of immunosuppression such 
as bone marrow transplantation.7,8 In immunocompromised individu-
als, infection with human immunodeficiency virus (HIV) correlation 
with long- term complications by HEV infection is less well estab-
lished.9,10 Most studies have found a higher seroprevalence of HEV 
in HIV- infected patients, but there is less convincing evidence of 
chronicity.9,11,12 Interestingly nonetheless, several studies found an 
increased seroprevalence of HEV in cirrhotics with HIV, compared 
to HIV- infected non- cirrhotic patients, implicating the virus as a po-
tential risk factor for progression of liver disease to advanced fibrosis 
stages in this setting.13,14 Overall, there is a paucity of knowledge in 
regard to risk factors that affect prevalence or predispose to HEV 
infection in individuals with HIV.9,10 Recent studies have described 
novel factors implicated in infection and mortality of HEV infection 
during pregnancy.3,15 In this regard, a mutation in the progesterone 
receptor (PR) has been reported to be associated with acute viral 
hepatitis and liver failure from HEV in pregnant women.4 This mu-
tation, called PROGINS (progesterone receptor G insert), consists 
of two single nucleotide polymorphisms and a G- intron insert, and 
it has been reported to render the PR less functional.16 Therefore, 
during pregnancy, progesterone could have a differential effect on 
peripheral lymphocytes expressing PR in individuals with the muta-
tion predisposing to HEV infection. Since lymphocytes, particularly 
CD4+ lymphocytes, are most affected during HIV infection, it is pos-
sible that a second “immune hit” could predispose certain patients 
to other viral infections. In this study, we addressed whether the 
PR mutation PROGINS represents a risk factor for HEV infection in 
HIV- positive individuals.
2  | MATERIALS AND METHODS
2.1 | Patients
2.1.1 | HIV- positive patients
HIV- positive patients from the Department of Infectious Diseases 
of the Erasmus Medical Center between June 2006 and June 2011 
were selected as described before.17 The median age of patients was 
42 years, 73% were males and 80% were on antiretroviral therapy. 
EDTA- plasma samples stored at −80°C were used for the detection 
of HEV- specific antibodies and HEV- RNA. Healthy Controls: Samples 
present in our serum biobank who voluntarily donated serum and 
blood for research purposes. They remain anonymous and we do not 
keep information regarding age or gender.
We obtained approval for our study by the Medical Ethical Review 
board of the Erasmus Medical Center (reference number MEC- 2011- 
438). Informed consent was requested in those where PBMC samples 
were obtained.
2.2 | HEV- specific antibody detection
For both HEV- specific IgM and HEV- specific IgG detection in serum 
or EDTA- plasma samples, the commercially available enzyme- linked 
immunosorbent assay (ELISA) (Wantai) was used according to the 
manufacturer’s instructions.
2.3 | Serum IL- 10 and IL- 12 detection
Cytokine levels were determined using the human IL- 10 high sensitiv-
ity and the human IL- 12p70 ELISA kit (eBioscience).
2.4 | Host genotyping
Competitive allele- specific PCR assays (KASP™, LGC Genomics, 
Huddleston, UK) were employed for the detection of the reference 
SNP rs1042838. The PROGINS allele was defined by the exon 4 mis-
sense SNP rs1042838, Val660Leu as previously described.4 Serum 
samples stored at −80°C were used for DNA extraction and geno-
typing procedures which were carried out at LGC genomics. Purified 
genomic DNA of ≥5 ng was used for genotyping. Genotypes were 
assigned using all of the data from HIV samples simultaneously and 
healthy controls on a second instance. Genotype sequences were de-
rived from NCBI.
2.5 | Stimulation and intracellular cytokine 
analysis of T cells and NK cells
2.5.1 | T- cell stimulation
Peripheral blood mononuclear cells (PBMCs) from healthy individu-
als and patients (obtained from fresh blood and later frozen) were 
cultured in a 96- well plate. Cells were stimulated with PMA (50 ng/
mL) and ionomycin (400 ng/mL, both from Sigma) for 1 hour, with 
or without progesterone 1 or 10 μg, or progesterone 10 μg alone 
(Sigma Aldrich), at 37°C. Brefeldin A was added and the cells were 
incubated for another 4 hours. Samples were fixed, permeabilized 
and stained with IL- 2 APC, CD4 PE- Cy7, CD8 eFluor450, CD3 
FITC (all eBioscience). Cytokine- producing cells were detected by 
flow cytometry (FACS Canto- II, BD). NK cell stimulation: PBMCs 
from healthy individuals were cultured in a 24- well plate. Cells 
Key points
• Hepatitis E infection is more frequent in HIV-positive pa-
tients and the only known risk factor for hepatitis E in 
HIV is CD4 counts
• We found that the presence of the PROGINS mutation is 
associated with HEV infection in HIV-positive patients
• Individuals with PROGINS mutations showed a distinc-
tive immune response with altered serum levels of IL-10 
as well as decreased T-cell stimulation
• Our manuscript provides new insight into mechanisms of 
HEV infection in immunosuppression
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were stimulated with IL- 12 and IL- 18 alone or with pre- treatment 
with progesterone 1 or 10 μg, or progesterone 10 μg alone. After 
18 hours, brefeldin A was added to the cultures and the cells were 
incubated for an additional 4 hours. Cellular activation and surface 
markers were measured using anti- CD3 PacificBlue (OKT3, eBiosci-
ence), anti- CD56 PE (MY31, BD) and anti- CD69 APC (L78, BD), fol-
lowed by fixation with 2% formaldehyde, and permeabilization with 
anti- IFN- γ FITC (BD). Activated and cytokine- producing NK cells 
were assessed by flow cytometry and analysed using FlowJo ver-
sion 10.1 (Tree Star Inc).
2.6 | Statistical analysis
Baseline characteristics were compared between HEV IgG positive 
and negative patients expressing PROGINS mutation or wild- type 
progesterone receptor (PR), using Fisher exact test (between HEV+ 
and −and presence or absence of PROGINS). Quantitative compari-
sons were performed using nonparametric Wilcoxon test or Mann- 
Whitney test (for values that did not show a normal distribution). For 
comparison of stimulation of T or NK cells, paired t- test was used to 
evaluate median of responses. A P value <.05 was considered statisti-
cally significant.
3  | RESULTS
3.1 | PROGINS mutation in HIV+ and healthy 
controls
A total of 64 HIV+ patients and 187 healthy controls were evaluated 
for the presence of PROGINS. Of those HIV+, 26 were seropositive 
for HEV (HIV+/HEV+) and 38 (age- matched) were HEV seronegative. 
The median age for HIV+/HEV+ individuals was 47 years (IQR 42- 53) 
and their median CD4 count 350/mm3. Median age for HIV+/HEV− 
individuals was 40 years (IQR 33- 46) with a median CD4 count of 280/
mm3 (Table 1). We found 8 out of 26 (30%) HIV+/HEV+ individuals 
to express the PROGINS mutation compared to 1 out of 38 (2%) of 
HIV+/HEV− individuals (P = .009, Figure 1A). Baseline characteristics 
of the individuals expressing wild- type PR or the PROGINS mutation 
were similar, with a median of 47 years for both groups and a median 
CD4 count of 340/mm3 for those with wild- type PR, and 487/mm3 for 
those with PROGINS mutation (Table 1). There was a higher percent-
age of males among individuals expressing the PROGINS mutation 
compared to wild- type PR (86% vs 66%), but the difference was not 
significant, suggesting that the higher seroprevalence of HEV in HIV- 
positive individuals with the PROGINS mutation cannot be explained 
by age, gender or CD4 count. A similar analysis of the PROGINS mu-
tation in 187 healthy controls available in our serum bank showed 
that 26 out of 187 controls (14%) carried the PROGINS mutation. 
Interestingly, in a subset of 70 of the healthy controls, eight (11%) 
were positive for HEV IgG and only two of those expressed PROGINS 
mutation (Table S1).
3.2 | Cytokine levels in the presence or absence of 
PROGINS in HIV
We further analysed whether the presence of the PROGINS mu-
tation had an impact on the modulation of immune parameters in 
HIV- positive individuals. We performed ultra- sensitive ELISA as-
says to determine the levels of IL- 10 and IL- 12 in serum of 5 HIV+/
HEV− samples with wild- type PR, 5 HIV+/HEV+ samples with wild- 
type PR and 5 HIV+/HEV+ samples that carried the PROGINS mu-
tation. These samples were obtained in duplicate at two different 
time points with confirmation of liver enzymes being under normal 
limits (to rule out external inflammatory stimuli). We found that lev-
els of IL- 10 were significantly lower in samples that expressed the 
PROGINS mutation compared to those with wild- type PR, either 
HEV+ or HEV− (P = .04 and .02, respectively; Figure 1B). Levels of 
IL- 12 were elevated in those with PROGINS mutation, although this 
trend was not significant (P = .05), likely due to the low number of 
samples (Figure 1C).
HIV+ HEV+ N:26 
N (%)
HIV+ HEV− N:38 
N (%)
Controls N:187 
N (%)
PROGINS mutation 
rs1042838
8 (30%) 1 (2%) 26 (14%)
HEV serostatus HEV+ HEV−
Median age (IQR) 47 (42- 53) 40 (33- 46)
Male percentage 70% 70%
CD4+ T cell counta 
(IQR)
350 (230- 580) 280 (200- 410)
Mutation status PROGINS+ PROGINS−
Median age (IQR) 47 (40- 63) 47 (41- 53)
Male percentage 87% 66%
CD4+ T- cell count 
(IQR)
487 (279- 592) 340 (121- 470)
aCD4 count/mm3.
IQR, Interquartile Range.
TABLE  1 Patient characteristics
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3.3 | Role of PROGINS in immune 
functional response
To further understand the role of PROGINS in immune modulation 
under stress, we performed functional assays in CD4+, CD8+ T cells 
and NK cells. Since PBMCs from HIV- positive individuals with the mu-
tation were not available, we performed the assays (in duplicate) with 
samples from five healthy controls who carried wild- type PR and five 
samples with the PROGINS mutation. Upon stimulation with PMA/
ionomycin, we found lower cytokine production in CD4+ and CD8+ 
T cells from samples carrying the PROGINS mutation compared to 
those with wild- type PR, and this reduced response was more evident 
when we used synthetic progesterone (Figure S1A,B). This effect was 
statistically significant in CD4+ T cells, but not in CD8+ T cells, and was 
observed in multiple independent experiments. In contrast to the ef-
fect on T- cell function, we found no differential response upon stimu-
lation of NK cells with IL- 12 and IL- 18 regardless of the presence of 
the mutation or not (Figure S1C).
4  | DISCUSSION
In this study, we describe for the first time a mutation in the pro-
gesterone receptor associated to HEV seroprevalence in HIV- infected 
patients. The presence of the mutation led to lower IL- 10 levels in 
serum, and a decreased functionality of CD4+ and CD8+ T cells upon 
polyclonal stimulation.
We show that the PROGINS SNP is found at a frequency of 14% 
in a large cohort of healthy volunteers, and the same frequency was 
observed in all HIV- positive samples combined (9 out of 64, 14%). 
However, stratification of PROGINS frequency between HEV- positive 
and HEV- negative individuals within the HIV- infected group demon-
strated a staggering difference between both populations with 30% 
of HIV+/HEV+ expressing PROGINS versus 2% in those HIV+/HEV−. 
These findings suggest that the presence of the mutation is a poten-
tial risk factor for HEV in HIV- infected individuals. Altered immunity 
in HIV patients is well described, even in those with viral control by 
effective antiretroviral therapy.18 Our findings suggest that additional 
immunomodulation in patients carrying the PROGINS mutation may 
enhance susceptibility to HEV infection or development of an immune 
response to it.
Our experiments in healthy volunteers expressing the PROGINS 
mutation revealed a decreased response to stimulation of CD4+ and 
CD8+ T cells. Although it is difficult to prove causality, it is reason-
able to speculate that weaker T- cell responses in patients carrying the 
PROGINS mutation may result in higher HEV seroprevalence in this 
group. The suggestion that the PROGINS mutation acts as a factor 
related to an altered immunity based on a differential response to pro-
gesterone in T cells is relevant, and may also be pertinent for other dis-
eases in which the PROGINS mutation has been evaluated and found 
to be a potential risk factor, such as breast and ovarian cancer.19,20 
Importantly, in contrast to T cells, we found that NK cells from indi-
viduals with PROGINS mutations have a similar functionality to those 
with wild- type progesterone receptors.
It was previously reported that the PROGINS mutation allows 
for infection of HEV during pregnancy via modulation of immune 
responses.4 In this study, it was hypothesized that differential IL- 10 
modulation due to the presence of the PROGINS mutation could 
F IGURE  1 Presence and effect of 
PROGINS in HIV/HEV- seropositive 
individuals and controls. (A) Pie chart 
showing frequency of PROGINS as a 
percentage in HIV+/HEV+ (N:26); HIV+/
HEV- individuals (N:38) and healthy 
controls (N:187). Dark colouring indicates 
presence of PROGINS, grey colouring 
indicates wild- type progesterone receptor. 
(B) Serum levels of IL- 10 (in 10 individuals, 
5 each group) measured with ultra- sensitive 
ELISA. Y- axis represents levels of IL- 10 
in pg/ml; X- axis represents the different 
groups. (C) Serum level of IL- 12 fraction 
p70 in HIV+ individuals (in 10 individuals, 
5 each group) measured by ELISA. Y- axis 
represents levels of IL- 12p70 in pg/ml; 
X- axis represents the different groups. 
SNP = single nucleotide polymorphism 
rs1042838 (indicative of PROGINS)
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affect Th1/Th2 regulation during pregnancy hence allowing for HEV 
infection.4 However, in our study, we found reduced serum IL- 10 lev-
els in those with PROGINS mutations, suggesting that IL- 10 mediated 
inhibition of T- or NK- cell responses in unlikely to contribute to the 
enhanced HEV seroprevalence in the HIV setting.
None of the HEV- seropositive individuals had detectable HEV 
RNA in blood, and we cannot therefore address this association to 
the development of chronic HEV infection. In order for the PROGINS 
mutation to be the dominant risk factor for HEV, one would have to 
assume complete exposure to HEV in the entire population. Although 
this is somewhat unlikely, it is possible that most individuals are ex-
posed to risk factors associated to HEV such as pork consumption and 
ingestion of charcuterie.9,14
Overall, our findings show for the first time an association with 
the PR mutation PROGINS and infection with HEV in HIV- positive pa-
tients, likely related to alterations in the immune milieu. A larger study 
involving individuals receiving organ transplant and other forms of im-
munosuppression is warranted.
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